NORTECH SYSTEMS INC 10-K/A

Item 8. Financial Statements and Supplementary Data PAGE Report of Independent Registered Public Accounting Firm (PCAOB Firm ID 23 ) 29 Consolidated Financial Statements: Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December 31, 2025 and 2024 30 Consolidated Balance Sheets as of December 31, 2025 and 2024 31 Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024 32 Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2025 and 2024 33 Notes to Consolidated Financial Statements 34-52 (The remainder of this page was intentionally left blank.) 28 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and the Board of Directors of Nortech Systems Incorporated and Subsidiaries: Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Nortech Systems Incorporated and Subsidiaries (the “Company”) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive income (loss), shareholders’ equity, and cash flows for the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2025 and 2024, and the consolidated results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matter The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. Assessment of Impairment of Long-Lived Assets Critical Audit Matter Description As described in Note 1 to the consolidated financial statements, the Company reviews property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset (asset group) may not be recoverable. An impairment loss is recognized when the carrying amount of an asset exceeds the estimated undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss recorded is calculated by the excess of the asset’s carrying value over its fair value. Management identified triggering events during the year ended December 31, 2025, that indicated that the property, plant and equipment could be impaired and performed an impairment test. While the impairment test did not result in the recording of any impairment loss, the impairment test is complex and judgmental due to management’s use of subjective assumptions when determining the asset groups to be evaluated for impairment, estimating expected future cash flows to be provided by operating activities of the identified asset groups, and estimating fair values of the assets or asset groups when applicable. How We Addressed the Matter in Our Audit Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. Our audit procedures related to the assessment of impairment of long-lived assets included the following, among others: ● Evaluated the appropriateness of the asset groups used in performing management’s impairment analysis. ● Tested management’s assumptions used in estimating the cash flows expected to be provided by operating activities of the asset groups, including the completeness and accuracy of the underlying data supporting the assumptions. ● Performed a sensitivity analysis over the growth rates, operating margin, and other assumptions used in management’s analysis compared to historical performance. ● Compared previously forecasted financial information to historical results to assess the reasonableness of future forecasted financial information used in the analysis. ● Evaluated audit evidence from events and transactions occurring after the measurement date. /s/ Baker Tilly US, LLP Minneapolis, Minnesota March 26, 2026 We have served as the Company’s auditor since 2017. 29 NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024 (IN THOUSANDS, EXCEPT SHARE DATA) 2025 2024 Net sales $ 118,365 $ 128,133 Cost of goods sold 100,359 111,411 Gross profit 18,006 16,722 Operating expenses Selling 4,803 3,446 General and administrative 10,790 11,709 Research and development 1,172 1,191 Restructuring charges 266 571 Total operating expenses 17,031 16,917 Income (loss) from operations 975 ( 195 ) Other expense Interest expense ( 964 ) ( 744 ) Income (loss) before income taxes 11 ( 939 ) Income tax expense 263 356 Net loss $ ( 252 ) $ ( 1,295 ) Net loss per common share: Basic (in dollars per share) $ ( 0.09 ) $ ( 0.47 ) Weighted average number of common shares outstanding - basic (in shares) 2,776,680 2,755,041 Diluted (in dollars per share) $ ( 0.09 ) $ ( 0.47 ) Weighted average number of common shares outstanding – diluted (in shares) 2,776,680 2,755,041 Other comprehensive income (loss) Foreign currency translation 268 ( 445 ) Comprehensive income (loss), net of tax $ 16 $ ( 1,740 ) See accompanying notes to consolidated financial statements. 30 NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2025 AND 2024 (IN THOUSANDS, EXCEPT SHARE DATA) 2025 2024 ASSETS Current assets: Cash $ 1,655 $ 916 Accounts receivable, less allowances of $ 161 and $ 196 , respectively 16,998 14,875 Inventories, net 20,695 21,638 Contract assets 15,184 13,792 Prepaid assets and other assets 1,618 4,094 Total current assets 56,150 55,315 Property and equipment, net 5,203 6,232 Operating lease assets 7,016 8,139 Deferred tax assets 3,394 2,575 Other intangible assets, net 156 174 Total assets $ 71,919 $ 72,435 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Line of credit $ 7,000 $ - Accounts payable 12,809 11,582 Accrued payroll and commissions 1,822 1,841 Customer deposits 5,386 5,140 Current portion of operating leases 1,332 1,175 Current portion of finance lease obligations 274 143 Other accrued liabilities 1,221 1,547 Total current liabilities 29,844 21,428 Long-term liabilities: Long-term line of credit - 8,634 Long-term operating lease obligations, net of current portion 6,476 7,773 Long-term finance lease obligations, net of current portion 626 311 Other long-term liabilities 426 284 Total long-term liabilities 7,528 17,002 Total liabilities 37,372 38,430 Shareholders’ equity: Preferred stock, $ 1 par value; 1,000,000 shares authorized; 250,000 shares issued and outstanding 250 250 Common stock - $ 0.01 par value; 9,000,000 shares authorized; 2,786,134 and 2,760,793 shares issued and outstanding, respectively 28 28 Additional paid-in capital 17,855 17,329 Accumulated other comprehensive loss ( 709 ) ( 977 ) Retained earnings 17,123 17,375 Total shareholders’ equity 34,547 34,005 Total liabilities and shareholders’ equity $ 71,919 $ 72,435 See accompanying notes to consolidated financial statements. 31 NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024 (IN THOUSANDS) 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ ( 252 ) $ ( 1,295 ) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation 1,270 1,649 Amortization 18 89 Compensation on stock-based awards 503 461 Deferred taxes ( 558 ) ( 12 ) Change in accounts receivable allowance ( 35 ) ( 162 ) Change in inventory reserves 401 280 Gain on disposal of property and equipment - ( 23 ) Changes in current operating items Accounts receivable ( 1,951 ) 4,405 Inventories 485 ( 400 ) Contract assets ( 1,393 ) 689 Prepaid expenses and other assets 2,482 ( 2,049 ) Income taxes ( 29 ) ( 333 ) Accounts payable 1,346 ( 3,956 ) Accrued payroll and commissions ( 30 ) ( 2,289 ) Customer deposits 244 1,071 Other accrued liabilities 242 ( 375 ) Net cash provided by (used in) operating activities 2,743 ( 2,250 ) CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from sale of property and equipment 504 7 Purchases of property and equipment ( 661 ) ( 1,270 ) Net cash used in investing activities ( 157 ) ( 1,263 ) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from line of credit 101,785 129,793 Payments to line of credit ( 103,480 ) ( 126,944 ) Proceeds from notes payable - 345 Principal payments on financing leases ( 195 ) ( 367 ) Share repurchases - ( 100 ) Stock award exercises 23 38 Net cash (used in) provided by financing activities ( 1,867 ) 2,765 Effect of exchange rate changes on cash 20 ( 11 ) Net change in cash 739 ( 759 ) Cash - beginning of year 916 1,675 Cash - end of year $ 1,655 $ 916 Supplemental disclosure of cash flow information: Cash paid for interest $ 925 $ 764 Cash paid for income taxes 751 473 Supplemental noncash investing and financing activities: Property and equipment purchases in accounts payable $ 81 $ 254 Property acquired under operating leases - 2,336 Equipment acquired under finance leases 637 256 See accompanying notes to consolidated financial statements. 32 NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024 (IN THOUSANDS) Accumulated Additional Other Total Preferred Stock Common Stock Paid-In Comprehensive Retained Shareholders’ Shares Amount Shares Amount Capital Loss Earnings Equity Balance as of December 31, 2023 250 $ 250 2,740 $ 27 $ 16,929 $ ( 532 ) $ 18,670 $ 35,344 Net loss - - - - - - ( 1,295 ) ( 1,295 ) Foreign currency translation adjustment - - - - - ( 445 ) - ( 445 ) Compensation on stock-based awards - - - - 461 - - 461 Stock repurchases - - ( 8 ) ( 1 ) ( 99 ) - - ( 100 ) Stock award exercises - - 29 2 38 - - 38 Balance as of December 31, 2024 250 $ 250 2,761 $ 28 $ 17,329 $ ( 977 ) $ 17,375 $ 34,005 Balance 250 $ 250 2,761 $ 28 $ 17,329 $ ( 977 ) $ 17,375 $ 34,005 Net loss - - - - - - ( 252 ) ( 252 ) Foreign currency translation adjustment - - - - - 268 - 268 Compensation on stock-based awards - - - - 503 - - 503 Stock award exercises - - 25 - 23 - - 23 Balance as of December 31, 2025 250 $ 250 2,786 $ 28 $ 17,855 $ ( 709 ) $ 17,123 $ 34,547 Balance 250 $ 250 2,786 $ 28 $ 17,855 $ ( 709 ) $ 17,123 $ 34,547 See accompanying notes to consolidated financial statements. 33 NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024 (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements of Nortech Systems Incorporated and Subsidiaries (“the Company”, “we”, “our”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Nature of Business The Company, organized in December 1990, is a provider of engineering design and manufacturing solutions for complex electromedical devices, electromechanical systems, assemblies and components headquartered in Maple Grove, Minnesota, a suburb of Minneapolis, Minnesota. We maintain facilities and operations in Minnesota in the United States; Monterrey, Mexico; and Suzhou, China. Principles of Consolidation The consolidated financial statements include the accounts of Nortech Systems Incorporated and its wholly-owned subsidiaries, Manufacturing Assembly Solutions of Monterrey, Inc. and Nortech Systems Hong Kong Company, Limited as well as its wholly-owned subsidiary, Nortech Systems Suzhou Company, Limited. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our consolidated financial statements. Estimates also affect the reported amounts of net sales and expense during the reporting period. Significant items subject to estimates and assumptions include the valuation allowance for inventories, the measurement of revenue recognized over time, realizability of deferred tax assets and long-lived asset recovery. Actual results could differ from those estimates. 34 Accounts Receivable and Allowance for Expected Losses We grant credit to customers in the normal course of business. Accounts receivable is unsecured and presented net of an allowance for doubtful accounts. The allowance for expected losses was $ 161 and $ 196 as of December 31, 2025 and 2024, respectively. When we record customer receivables and contract assets arising from net sales transactions, we record an allowance for credit losses for the current expected credit losses inherent in the asset over its expected life. The allowance for credit losses is a valuation account deducted from the cost basis of the assets to present their net carrying value at the amount expected to be collected. Each period, the allowance for credit losses is adjusted through earnings to reflect expected credit losses over the remaining lives of the assets. We estimate expected credit losses based on relevant information about past events, including historical write-offs of bad debts, customer concentrations, customer creditworthiness, current economic trends and changes in customer payment terms that affect the collectability of the reported amount. When measuring expected credit losses, we pool assets with similar country risk and credit risk characteristics. Changes in the relevant information may significantly affect the estimates of expected credit losses. Assets are written off when we determine them to be uncollectible. Write-offs are recognized as a deduction from the allowance for credit losses. Inventories Inventories consist of finished goods, raw materials and work-in-process and are stated at the lower of average cost (which approximates first-in, first-out) or net realizable value. Costs include material, labor, and overhead required in the production of our products. Inventory reserves are maintained for inventories that may have a lower value than stated or quantities in excess of future production needs. We regularly review inventory quantities on-hand for excess and obsolete inventory and, when circumstances indicate, incur charges to write down inventories to their net realizable value. The determination of a reserve for excess and obsolete inventory involves management exercising judgment to determine the required reserve, considering future demand, product life cycles, introduction of new products and current market conditions. Inventories are as follows as of December 31, SCHEDULE OF INVENTORIES 2025 2024 Raw materials $ 20,575 $ 21,122 Work in process 1,003 892 Finished goods 970 1,070 Reserves ( 1,853 ) ( 1,446 ) Total $ 20,695 $ 21,638 35 Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized, while maintenance and minor repairs are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in operations. Leasehold improvements are depreciated over the shorter of their estimated useful lives or their remaining lease terms. All other property and equipment are depreciated by the straight-line method over their estimated useful lives, as follows: SCHEDULE OF ESTIMATED USEFUL LIVES (in years) Building 39 Leasehold improvements 3 - 15 Manufacturing equipment 3 - 7 Office and other equipment 3 - 7 Property and equipment are as follows as of December 31, SCHEDULE OF PROPERTY AND EQUIPMENT 2025 2024 Land $ - $ 148 Building and leasehold improvements 3,927 6,027 Manufacturing equipment 19,444 20,807 Office and other equipment 6,680 6,523 Accumulated depreciation and amortization ( 24,848 ) ( 27,273 ) Total property and equipment, net $ 5,203 $ 6,232 Long-Lived Asset Impairment We evaluate long-lived assets, primarily property and equipment, whenever current events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability for assets to be held and used is based on our projection of the undiscounted future operating cash flows of the underlying assets. To the extent such projections indicate that future undiscounted cash flows are not sufficient to recover the carrying amounts of related assets, a charge might be required to reduce the carrying amount to equal estimated fair value. As of December 31, 2025, the Company’s common stock was trading at a value less than the Company’s net equity value. As such, the Company evaluated future undiscounted cash flows and determined that no long-lived asset impairment was required as of December 31, 2025. No impairment of long-lived assets was recorded during the years ended December 31, 2025 or 2024. Preferred Stock Preferred stock issued is non-cumulative and nonconvertible. The holders of the preferred stock are entitled to a non-cumulative dividend of 12 % when and if declared. In liquidation, holders of preferred stock have preference to the extent of $ 1.00 per share plus dividends declared but unpaid. No preferred stock dividends were declared or paid during the years ended December 31, 2025 and 2024. Revenue Recognition Our net sales are comprised of product, engineering services and repair services. All net sales are recognized when the Company satisfies its performance obligation(s) under the contract by transferring the promised product or service to our customer either when (or as) our customer obtains control of the product or service, with the majority of our net sales being recognized over time including goods produced under contract manufacturing agreements and services net sales. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of our contracts have a single performance obligation, as the promise to transfer products or services is not separately identifiable from other promises in the contract and, therefore, not distinct. Net sales are measured as the amount of consideration we expect to receive in exchange for transferring products or providing services. As such, net sales are recorded net of returns, allowances and customer discounts. Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from net sales) basis. Shipping and handling costs are included in cost of goods sold . We pay sales commissions on new business generated. Because the related amortization period for these incremental contract acquisition costs is one year or less, the Company has elected the practical expedient and therefore expenses these costs as incurred. Additionally, the Company has elected the practical expedient related to significant financing components and does not assess whether a contract includes a significant financing component when the period between the transfer of the promised goods or services and customer payment is one year or less. 36 The majority of our net sales are derived from the transfer of goods produced under contract manufacturing agreements which have no alternative use, and we have an enforceable right to payment for our performance completed to date. Our performance obligations within our contract manufacturing agreements are generally satisfied over time as the goods are produced based on customer specifications and we have an enforceable right to payment for the goods produced. If these requirements are not met, the net sales are recognized at a point in time, generally upon shipment. Net sales under contract manufacturing agreements that was recognized over time accounted for approximately 76 % our net sales for both the years ended December 31, 2025 and 2024. Net sales under these agreements are generally recognized over time using an input measure based upon the proportion of actual costs incurred. Accounting for contract manufacturing agreements involves the use of various techniques to estimate total net sales and costs. We estimate profit on these agreements as the difference between total estimated net sales and expected costs to complete the performance obligation within the terms of the agreement and recognize the respective profit as the goods are produced. The estimates to determine the profit earned on the performance obligation are based on contractual selling prices and historical cost of goods sold and represent our best judgement at the time. Changes in judgements on these above estimates could impact the timing and amount of net sales recognized with a resulting impact on the timing and amount of associated profit. On occasion our customers provide materials to be used in the manufacturing process and the fair value of the materials is included in net sales as noncash consideration at the point in time when the manufacturing process commences along with the same corresponding amount recorded as cost of goods sold. The inclusion of noncash consideration has no impact on overall profitability. Our net sales for services were less than 10% of our total sales for all periods presented, and accordingly, are included in net sales in the consolidated statements of operations and comprehensive income (loss). Contract Assets Contract assets, recorded as such in the consolidated balance sheets, consist of unbilled amounts related to net sales recognized over time. Changes in the contract assets balance during the years ended December 31, 2025 and 2024 were as follows: SCHEDULE OF CONTRACT ASSETS Balance outstanding as of December 31, 2023 $ 14,481 Increase (decrease) attributed to: Amounts transferred over time to contract assets 97,724 Reversal of allowance for current expected credit losses 4 Amounts invoiced during the period ( 98,417 ) Balance outstanding as of December 31, 2024 $ 13,792 Increase (decrease) attributed to: Amounts transferred over time to contract assets 89,530 Allowance for current expected credit losses ( 1 ) Amounts invoiced during the period ( 88,137 ) Balance outstanding as of December 31, 2025 $ 15,184 We expect substantially all the remaining performance obligations for the contract assets recorded as of December 31, 2025, to be transferred to receivables within 90 days, with any remaining amounts to be transferred within 180 days. We bill our customers upon shipment with payment terms of up to 120 days. Accounts receivables are presented separately on the consolidated balance sheets. Contract Liabilities Contract liabilities, recorded as customer deposits, were $ 4,068 at January 1, 2024 and $ 5,386 and $ 5,140 at December 31, 2025 and 2024, respectively. Contract liabilities primarily relate to customer prepayments, generally to purchase customer-specific inventory, and billings in advance of the Company satisfying its performance obligations. Revenue recognized during the year ended December 31, 2025 that was included in the contract liability balance at the beginning of the period was $ 500 . Changes between periods represent the timing of customer deposits and the satisfaction of performance obligations. 37 The following tables summarize our net sales by market for the years ended December 31, 2025 and 2024: SCHEDULE OF NET SALES BY MARKET Year Ended December 31, 2025 Product/ Service Transferred Over Time Product Transferred at Point in Time Noncash Consideration Total Net Sales by Market Medical Device $ 22,361 $ 7,387 $ 2,182 $ 31,930 Medical Imaging 31,908 7,996 95 39,999 Industrial 22,152 8,153 635 30,940 Aerospace and Defense 13,109 2,124 263 15,496 Total net sales $ 89,530 $ 25,660 $ 3,175 $ 118,365 Year Ended December 31, 2024 Product/ Service Transferred Over Time Product Transferred at Point in Time Noncash Consideration Total Net Sales by Market Medical Device $ 24,085 $ 7,487 $ 3,064 $ 34,636 Medical Imaging 29,362 8,104 26 37,492 Industrial 25,652 8,620 1,245 35,517 Aerospace and Defense 18,625 1,658 205 20,488 Total net sales $ 97,724 $ 25,869 $ 4,540 $ 128,133 Noncash consideration represents material provided by the customer used in the build of the product. Product Warranties We provide limited warranty for the replacement or repair of defective product within a specified time period after the sale at no cost to our customers. We make no other guarantees or warranties, expressed or implied, of any nature whatsoever as to the goods including, without limitation, warranties to merchantability, fit for a particular purpose or non-infringement of patent or the like unless agreed upon in writing. We estimate the costs that may be incurred under our limited warranty and provide a reserve based on actual historical warranty claims coupled with an analysis of unfulfilled claims at the balance sheet date. Our warranty claim costs are not material given the nature of our products and services. Advertising Advertising costs are charged to operations as incurred and aggregated to $ 114 and $ 83 for the years ended December 31, 2025 and 2024, respectively. Income Taxes We account for income taxes under the asset and liability method. Deferred income tax assets and liabilities are recognized annually for differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. We recognize interest and penalties accrued on any unrecognized tax benefits as a component on income tax expense. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such positions are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Management must also assess whether uncertain tax positions as filed could result in the recognition of a liability for possible interest and penalties if any. Our estimates are based on the information available to us at the time we prepare the income tax provisions. Our income tax returns are subject to audit by federal, state, and local governments, generally three years after the returns are filed. These returns could be subject to material adjustments or differing interpretations of the tax laws. 38 Stock-Based Compensation We use a Black-Scholes option-pricing model to determine the grant date fair value of our service-based incentive awards and recognize the expense on a straight-line basis over the vesting period. We determine the grant date fair value of our market-based incentive awards using a lattice simulation model and recognize the expense on a straight-line basis over the vesting period. The grant date fair value of restricted stock units is determined based on the closing market price of the Company’s common stock on the date of grant, with compensation expense recognized ratably over the applicable vesting period. See Note 8 – “Incentive Plans” for additional information. Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding. Dilutive net income per common share assumes the exercise and issuance of all potential common stock equivalents in computing the weighted-average number of common shares outstanding using the treasury stock method, unless their effect is anti-dilutive. Basic and diluted weighted average shares outstanding were as follows: SCHEDULE OF BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING 2025 2024 Years Ended December 31, 2025 2024 Basic weighted average shares outstanding 2,776,680 2,755,041 Dilutive effect of outstanding stock options and non-vested restricted stock units 1 - - Diluted weighted average shares outstanding 2,776,680 2,755,041 1 The following items were excluded from the computation of diluted weighted-average shares outstanding as their inclusion would be anti-dilutive: a. For the year ended December 31, 2025, restricted stock units and stock options totaling 533,846 . b. For the year ended December 31, 2024, restricted stock units and stock options totaling 477,541 . Fair Value of Financial Instruments The carrying amounts of all financial instruments approximate their fair values. The carrying amounts for cash, accounts receivable, accounts payable, and other assets and liabilities approximate fair value because of the short maturity of these instruments. Based on the borrowing rates currently available to us for bank loans with similar terms and average maturities, the carrying value of our long-term debt and line of credit approximates its fair value. 39 Foreign Currency Transactions The functional currency for our Mexico subsidiary is the US dollar. Foreign exchange transaction gains and losses attributable to exchange rate movements related to transactions made in the local currency and on intercompany receivables and payables not deemed to be of a long-term investment nature are recorded in general and administrative expense. The functional currency for our China subsidiary is the Renminbi (“RMB”). Assets and liabilities of the China subsidiary are translated from RMB into U.S. dollars at period-end rates, while income and expense are translated at the weighted-average exchange rates for the period. The related translation adjustments are reflected as a foreign currency translation adjustment in accumulated other comprehensive loss within shareholders’ equity. Foreign currency translation gains (losses) increased consolidated shareholders’ equity by $ 268 for the year ended December 31, 2025 and decreased shareholder’s equity by $ 445 for the year ended December 31, 2024. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the consolidated statements of operations and comprehensive income (loss). Net foreign currency transaction gains or losses included in the determination of net loss was a gain of $ 120 and a loss of $ 137 for the years ended December 31, 2025 and 2024, respectively. Adoption of New Accounting Standards In December 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU enhances the transparency and decision usefulness of income tax disclosures and is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. The Company has adopted this ASU and the additional income tax disclosures are noted in Note 6, Income Taxes. 40 Recently Issued New Accounting Standards In November 2024, the FASB issued ASU No. 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU No. 2024-03”), which requires disaggregated expense information in the notes to the financial statements related to purchases of inventory, employee compensation, depreciation, intangible asset amortization and selling expenses for each statement of earnings line item that contains those expenses. ASU No. 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The guidance is to be applied on a prospective basis with the option to apply the standard retrospectively; this ASU allows for early adoption. The Company is currently evaluating the impact of this ASU on its consolidated financial statements disclosures. In July 2025, the FASB issued ASU 2025-05, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU No. 2025-05”), which reduces the complexity of applying credit losses to current accounts receivable and current contract assets arising from transactions accounted for under Topic 606 (revenue from contracts with customers). ASU 2025-05 is effective for annual and interim reporting periods beginning after December 15, 2025. The Company is currently evaluating the impact of this ASU on its consolidated financial statements disclosures. NOTE 2. CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash, accounts receivable, and contract assets. We maintain our excess cash balances in checking accounts primarily at two financial institutions, one in the United States and one in China. The account in the United States may at times exceed federally insured limits. The Company’s $ 1,655 cash balance as of December 31, 2025, included approximately $ 517 and $ 137 that was held at banks located in China and Mexico, respectively. We grant credit to customers in the normal course of business and generally do not require collateral on our accounts receivable. We have certain customers whose revenue individually represented 10% or more of net sales, or whose accounts receivable balances or contract asset balances individually represented 10% or more of gross accounts receivable. Customers who represent 10% or more of net sales for years ended December 31, 2025 and 2024 are as follows: SCHEDULE OF NET SALES CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS 2025 2024 Year Ended December 31, 2025 2024 Customer A 32 % 28 % Customer B 10 % - Total 42 % 28 % 41 Customers who represent 10% or more of accounts receivable and contract assets as of December 31, 2025 and 2024 are as follows: SCHEDULE OF ACCOUNTS RECEIVABLE CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS 2025 2024 Accounts Receivable as of December 31, 2025 2024 Customer A 20 % 23 % Customer C - % 13 % Total 20 % 36 % SCHEDULE OF CONTRACT ASSETS CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS 2025 2024 Contract Assets as of December 31, 2025 2024 Customer A 36 % 33 % Customer D 13 % 12 % Total 49 % 45 % Export sales from the U.S. represented approximately 3 % of net sales for both the years ended December 31, 2025 and 2024. NOTE 3. OTHER INTANGIBLE ASSETS Finite life intangible assets as of December 31, 2025 and 2024 are as follows: SCHEDULE OF INTANGIBLE ASSETS Customer Relationships Patents Total Balance as of January 1, 2024 $ 72 $ 191 $ 263 Amortization 72 18 89 Balance as of December 31, 2024 $ - $ 174 $ 174 Balance $ - $ 174 $ 174 Amortization - 18 18 Balance as of December 31, 2025 $ - $ 156 $ 156 Balance $ - $ 156 $ 156 Intangible assets are amortized on a straight-line basis over their estimated useful lives. The weighted average remaining amortization period of our intangible assets is 4.1 years. Of the patents value as of December 31, 2025, $ 71 are being amortized and $ 85 are in process as patents have not yet been issued. Amortization expense of finite life intangible assets was $ 18 and $ 89 for the years ended December 31, 2025 and 2024, respectively. Estimated future annual amortization expense (except projects in process) related to these assets is approximately as follows: SCHEDULE OF ESTIMATED FUTURE ANNUAL AMORTIZATION EXPENSE Year Amount 2026 $ 18 2027 18 2028 18 2029 12 2030 5 Thereafter - Total $ 71 42 NOTE 4. FINANCING ARRANGEMENTS On February 29, 2024, we closed on a $ 15,000 Senior Secured Revolving Line of Credit with Bank of America (the “BOA Revolver”). The BOA Revolver allows for borrowings at a defined base rate, or at the one, three or six month Secured Overnight Finance Rate, also known as “SOFR,” plus a defined margin. If the Company prepays SOFR borrowings before their contractual maturity, the Company has agreed to compensate the bank for lost margin, as defined in the BOA Revolver agreement. The Company is required to quarterly pay a 20-basis point fee on the unused portion of the BOA Revolver. The BOA Revolver requires the Company to maintain no more than 2.5 times leverage ratio and at least a 1.25 times minimum fixed charges coverage ratio, both of which are defined in the BOA Revolver agreement. These ratios are calculated based on trailing twelve-month results. There are no subjective acceleration clauses under the BOA Revolver that would accelerate the maturity of outstanding borrowings. The BOA Revolver contains certain covenants which, among other things, require the Company to adhere to regular reporting requirements, abide by shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures. The BOA Revolver is secured by substantially all the Company’s assets and expires on February 28, 2027. We were not in compliance with financial covenants related to the maximum operating expense contributions to our Mexican operations in the first and second quarters of 2024. We have received a waiver of this event of default from the bank. Amendments to the BOA Revolver On March 27, 2025, we amended (the “First Amendment”) the BOA Revolver to waive our non-compliance with the leverage ratio and minimum fixed charge ratio as of December 31, 2024, and March 31, 2025. Provisions of the First Amendment relating to the Company’s compliance with these ratios were replaced with provisions of the Second Amendment (described below). Provisions of the First Amendment relating to minimum EBITDA requirements of the Company were replaced with provisions of the Second Amendment (described below). Provisions of the First Amendment requiring the Company to maintain unrestricted cash and BOA Revolver availability (collectively, “Liquidity”) at specified levels were replaced with provisions of the Second Amendment (described below). The First Amendment requires the Company to provide incremental monthly reporting and increases the Company’s borrowing rate by one percent until the Company is in compliance with the original terms of the BOA Revolver. The First Amendment increases the borrowing rate for revolving loans by 100 basis points. On May 14, 2025, we further amended (the “Second Amendment”) the BOA Revolver, which amended the First Amendment in part, to defer the Company’s compliance with the leverage ratio and minimum fixed charge ratio until the fourth quarter of 2025 at which time the Company must maintain (a) a leverage ratio of 2.5 times for the year ended December 31, 2025 and for each twelve-month quarterly reporting period thereafter; and (b) a minimum fixed charge coverage ratio to 1.25 times for the year ended December 31, 2025 and for each twelve-month quarterly reporting period thereafter. The Company must also maintain adjusted EBITDA (earnings before interest, taxes depreciation and amortization), as defined in the BOA Revolver, as of the end of the second quarter of 2025 of at least $1,000, the third quarter of 2025 of at least $1,300 and the fourth quarter of 2025 and each quarter thereafter of at least $1,600. In addition, the Second Amendment requires the Company to always maintain Liquidity of at least $2,500. The Second Amendment shortened the duration of the BOA Revolver to June 30, 2026 and increases the borrowing rate by 25 basis points. On July 29, 2025, we amended the BOA Revolver (the “Third Amendment”) to extend the expiration of the BOA Revolver to August 31, 2026. On February 27, 2026, we entered into a Waiver and Amendment No. 4 to its Credit Agreement with Bank of America, N.A. (“Waiver and Amendment”). See footnote 13, Subsequent Events. Outstanding Borrowings The BOA Revolver, as amended, bears interest at a weighted-average interest rate of 7.8 % and 7.7 % as of December 31, 2025 and December 31, 2024, respectively. We had borrowings on our line of credit of $ 7,000 and $ 8,695 outstanding as of December 31, 2025 and 2024, respectively. As of December 31, 2025, we had unused availability on the line of credit of $ 8,000 , which is subject to a month end cap based on the previously noted minimum Liquidity. The decrease in the line of credit balance between the years is the result of timing of accounts payable payments. We have recorded the outstanding BOA Revolver amount of $ 7,000 at December 31, 2025 as a current liability on the condensed consolidated balance sheets. The Company had an interim funding agreement with a bank related to deposits made on equipment purchases funded through a finance lease when the equipment was received and operational. The equipment was received, and the lease agreements were finalized during the second quarter of 2025. As of December 31, 2025, we have no amounts outstanding on the interim funding agreement for equipment. On March 20, 2026, the Company repaid the BOA Revolver and entered into a new asset-backed line of credit. See footnote 13, Subsequent Events. 43 NOTE 5. LEASES We have operating leases for certain manufacturing sites, office space, and equipment. Most leases include the option to renew, with renewal terms that can extend the lease term from one 1 to five 5 years or more. Right-of-use lease assets and lease liabilities are recognized at the commencement date based on the present value of the remaining lease payments over the lease term which includes renewal periods we are reasonably certain to exercise. Our leases do not contain any material residual value guarantees or material restrictive covenants. As of December 31, 2025, we do not have material lease commitments that have not commenced. We have financing leases for certain property and equipment used in the normal course of business. The components of lease expense were as follows for the years ended December 31: SCHEDULE OF COMPONENTS OF LEASE EXPENSE Lease Cost 2025 2024 Operating lease cost $ 2,364 $ 2,318 Finance lease interest cost 42 25 Finance lease amortization expense 212 451 Total lease cost $ 2,618 $ 2,794 Supplemental balance sheets information related to leases was as follows as of December 31: SCHEDULE OF SUPPLEMENTAL CONDENSED CONSOLIDATED BALANCE SHEETS INFORMATION RELATED TO LEASES Balance Sheets Location 2025 2024 Assets Operating lease assets Operating lease assets $ 7,016 $ 8,139 Finance lease assets Property, plant and equipment 714 411 Total leased assets $ 7,730 $ 8,550 Liabilities Current Current operating lease liabilities Current portion of operating lease obligations $ 1,332 $ 1,175 Current finance lease liabilities Current portion of finance lease obligations 274 143 Noncurrent Long-term operating lease liabilities Long-term operating lease liabilities, net 6,476 7,773 Long-term finance lease liabilities Long-term finance lease obligations, net 626 311 Total lease liabilities $ 8,708 $ 9,402 Supplemental cash flow information related to leases was as follows for the years ended December 31: SCHEDULE OF SUPPLEMENTAL CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS INFORMATION 2025 2024 Operating Leases Cash paid for amounts included in the measurement of lease liabilities $ 1,806 $ 1,821 Operating lease assets obtained in exchange for lease obligations $ - $ 2,336 The operating lease assets obtained in exchange for lease obligations in the year ended December 31, 2024 was largely due to the renewal of our lease in Maple Grove and Milaca, Minnesota, as well as leasing of additional space in our Suzhou, China facility. Future maturities of lease liabilities were as follows: SCHEDULE OF FUTURE PAYMENTS OF LEASE LIABILITIES Operating Leases Finance Leases Total Operating Leases Finance Leases Total 2026 $ 1,873 $ 320 $ 2,193 2027 1,580 211 1,791 2028 1,569 211 1,780 2029 979 196 1,175 2030 900 76 976 Thereafter 3,769 - 3,769 Total lease payments $ 10,670 $ 1,014 $ 11,684 Less: interest ( 2,862 ) ( 114 ) ( 2,976 ) Present value of lease liabilities $ 7,808 $ 900 $ 8,708 44 The lease term and discount rate as of December 31, 2025 were as follows: SCHEDULE OF LEASE TERM AND DISCOUNT RATE Weighted-average remaining lease term (years) Operating leases 7.1 Finance leases 4.0 Weighted-average discount rate Operating leases 8.1 % Finance leases 6.7 % NOTE 6. INCOME TAXES The income tax expense consists of the following for the years ended December 31: SCHEDULE OF INCOME TAX EXPENSE 2025 2024 Current Federal $ 43 $ ( 287 ) State 26 22 Foreign 752 633 Deferred Federal ( 581 ) 127 State ( 117 ) ( 119 ) Foreign 140 ( 20 ) Income tax expense $ 263 $ 356 The statutory rate reconciliation is as follows for the years ended December 31: SCHEDULE OF INCOME TAX STATUTORY RATE RECONCILIATION 2025 2024 Statutory rate $ 2 $ ( 200 ) State income tax ( 97 ) ( 101 ) Effect of foreign operations 88 ( 63 ) Maquiladora tax 128 187 Cross-border tax laws 147 492 Research and development ( 73 ) 13 Nontaxble and nondeductable items 28 ( 21 ) US permanent differences 14 ( 46 ) Other 26 95 Income tax expense (benefit) $ 263 $ 356 On July 4, 2025, H.R. 1, the One Big Beautiful Bill Act (the “OBBB Act”), was enacted in the United States. The OBBB Act introduced several tax law changes relevant to the manufacturing industry. Key provisions include the restoration of 100% bonus depreciation for qualified property, expanded interest deductibility under Internal Revenue Code Section 163(j) and other international tax reforms affecting global supply chains and cross-border operations. The OBBB Act also reinstates immediate expensing for domestic research and development expenditures for tax years beginning after December 31, 2024, reversing prior rules that required capitalization and amortization of such costs. Due to the impact on GILTI provisions, the Company does not intend to take 100% bonus depreciation. It also does not intend to immediately expense R&D expenditures for 2025 or accelerate the deduction of previously capitalized R&D expenditures. Income and loss from operations before income taxes was derived from the following jurisdictions for the years ended December 31: SCHEDULE OF INCOME AND LOSS FROM OPERATIONS BEFORE INCOME TAX 2025 2024 United States $ ( 3,210 ) $ ( 3,284 ) Foreign 3,221 2,345 Total $ 11 $ ( 939 ) 45 Deferred tax assets (liabilities) consist of the following as of December 31: SCHEDULE OF DEFERRED TAX ASSETS (LIABILITIES) 2025 2024 Deferred tax assets Inventory $ 585 $ 535 Net operating losses 140 241 Stock-based compensation 337 277 Other accruals 45 94 Lease accounting lease liability 1,484 1,624 Capitalized research expenses 1,078 928 Tax credit carryforwards 210 151 Intangibles 351 422 Other 1,145 542 Total deferred tax assets 5,375 4,814 Deferred tax liabilities Lease accounting lease asset ( 1,399 ) ( 1,562 ) Withholding tax ( 360 ) ( 219 ) Prepaid expenses ( 171 ) ( 186 ) Property and equipment ( 353 ) ( 278 ) Other ( 58 ) ( 213 ) Total deferred tax liabilities ( 2,341 ) ( 2,458 ) Net deferred tax assets $ 3,034 $ 2,356 The Company regularly assesses the need for a valuation allowance related to our deferred income tax assets to determine, based on the weight of the available positive and negative evidence, whether it is more likely than not that some or all of such deferred assets will not be realized. In our assessments, the Company considers recent financial operating results, potential sources of taxable income, the reversal of existing taxable differences, taxable income in prior carryback years, if permitted under tax law, and tax planning strategies. Based on our most recent assessment, for the year ended December 31, 2025, we have concluded that our deferred income tax assets are more likely than not to be realized. Our consolidated balance sheets as of December 31, 2025 and 2024 have a deferred tax asset of $ 3,394 and $ 2,575 , respectively, related to our US taxable operations and a $ 360 and $ 219 , respectively, deferred tax liability included other long-term liabilities related to our Chinese taxes, for a net deferred tax asset of $ 3,034 and $ 2,356 , respectively. As of December 31, 2025, we have no US Federal net operating loss carryforward and a Minnesota net operating loss carryforward (pre-tax, post-apportionment) of approximately $ 2,100 . As of December 31, 2025, the Company has US Federal and Minnesota R&D tax credits of approximately $ 100 and $ 100 , respectively. These balances are recorded net of any uncertain tax position. The R&D credits have a 20-year carryforward for Federal purposes (begin to expire in 2044) and 15-year carryforward for Minnesota purposes (begin to expire in 2029) . 46 The tax effects from uncertain tax positions can be recognized in our consolidated financial statements, only if the position is more likely than not to be sustained on audit, based on the technical merits of the position. We recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The following tables set forth changes in our total gross unrecognized tax benefit liabilities, excluding accrued interest, for the years ended December 31, 2025 and 2024: SCHEDULE OF UNRECOGNIZED TAX BENEFIT LIABILITIES Balance as of January 1, 2024 $ 131 Tax positions - additions 13 Tax positions - reductions ( 47 ) Balance as of December 31, 2024 97 Tax positions - additions 12 Tax positions - reductions 1 Balance as of December 31, 2025 $ 110 Our policy is to accrue interest related to potential underpayment of income taxes with a corresponding increase in income tax expense. The liability for accrued interest as of December 31, 2025 and 2024 was not significant. Interest is computed on the difference between our uncertain tax benefit positions and the amount deducted or expected to be deducted in our filed tax returns. We are subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, we are no longer subject to federal and state and local income tax examinations for years before 2021. NOTE 7. 401(K) RETIREMENT PLAN We have a 401(k) profit sharing plan (the “401(k) Plan”), a defined contribution plan, covering substantially all of our U.S. employees. Employees are eligible to participate in the Plan after completing three months of service and attaining the age of 18 . Employees are allowed to contribute up to 60 % of their wages to the 401(k) Plan. We match 50 % of the employees’ contributions up to 6 % of covered compensation. We made contributions, net of forfeitures, of approximately $ 640 and $ 725 during the years ended December 31, 2025 and 2024, respectively. NOTE 8. INCENTIVE PLANS In May 2017, the shareholders approved the 2017 Stock Incentive Plan which authorized the issuance of 350,000 shares. An additional 50,000 , 175,000 , 100,000 and 100,000 shares were authorized by the shareholders in March 2020, May 2022, May 2023 and May 2024, respectively. Stock Options We estimate the fair value of share-based awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense in the consolidated statements of operations and comprehensive (loss) income over the requisite service periods. Because share-based compensation expense is based on awards that are ultimately expected to vest, share-based compensation expense will be reduced to account for estimated forfeitures. We estimate forfeitures at the time of grant and revise the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimates. 47 We used the Black-Scholes option-pricing model to calculate the fair value of option-based awards. Our determination of fair value of option-based awards on the date of grant using the Black-Scholes model is affected by our stock price as well as assumptions regarding several subjective variables. These variables include, but are not limited to, our expected stock price, volatility over the term of the awards, risk-free interest rate, and the expected life of the options. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected life of our stock options. The expected volatility and holding period are based on our historical experience. For all grants, the amount of compensation expense recognized has been adjusted for an estimated forfeiture rate, which is based on historical data. Weighted average stock option fair value assumptions and the weighted average grant date fair value of stock options granted were as follows: SCHEDULE OF WEIGHTED AVERAGE GRANT DATE FAIR VALUE OF STOCK OPTIONS GRANTED 2025 2024 Stock option fair value assumptions: Risk-free interest rate 3.80 - 4.14 % 3.83 - 4.40 % Expected life (years) 6.0 6.0 Dividend yield 0 % 0 % Expected volatility 58 % 58 % Weighted average grant date fair value of stock options granted $ 5.13 $ 6.49 Total compensation expense related to stock options was $ 290 and $ 243 for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, there was $ 618 of unrecognized compensation which will vest and expense over the next 2.3 years. Following is the status of option activity as of and for the years ended December 31, 2025 and 2024 as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Outstanding – January 1, 2024 458,700 $ 6.63 Granted 23,000 11.08 Exercised ( 12,300 ) 4.55 Forfeited ( 16,000 ) 10.23 Outstanding – December 31, 2024 453,400 $ 6.79 5.70 $ 1,654 Granted 48,382 8.58 Exercised ( 1,200 ) 3.98 Forfeited ( 10,400 ) 8.22 Outstanding – December 31, 2025 490,182 $ 6.91 5.14 $ 828 Exercisable on December 31, 2025 323,600 $ 5.53 3.78 $ 826 48 Restricted Stock Units (“RSUs”) Total compensation expense related to the RSUs were $ 213 and $ 218 for the years ended December 31, 2025 and 2024, respectively. Total unrecognized compensation expense related to the RSUs was $ 256 , which will vest over the next 1.3 years. Following is the status of restricted stock activity as of and for the years ended December 31, 2025 and 2024 as follows: SCHEDULE OF RESTRICTED STOCK ACTIVITY Shares Weighted- Average Remaining Vesting Term (in years) Aggregate Intrinsic Value Outstanding – January 1, 2024 27,000 Granted 15,141 Vested ( 16,500 ) Forfeited ( 1,500 ) Outstanding – December 31, 2024 24,141 0.3 $ 248 Granted 43,664 Vested ( 24,141 ) Forfeited - Outstanding – December 31, 2025 43,664 1.3 $ 324 NOTE 9. SEGMENT INFORMATION Our results of operations for the years ended December 31, 2025 and 2024 represent a single operating and reporting segment referred to as Contract Manufacturing within the EMS industry. The Company operates in the Medical Device, Medical Imaging, Aerospace and Defense, and Industrial markets with over 50% of its net sales coming from the medical-related markets. We strategically direct production between our various manufacturing facilities based on a number of considerations to best meet our customers’ needs. Our plants generate net sales over several of the markets the Company serves. We share resources for sales, marketing, engineering, supply chain, information services, human resources, payroll, and all corporate accounting functions. Our chief operating decision maker (the “CODM”) is the Company’s President and Chief Executive Officer. The CODM regularly evaluates financial information on a consolidated basis to assess performance and allocate resources. The following table presents selected financial information with respect to the Company’s single operating segment for the years ended December 31, 2025 and 2024: SCHEDULE OF SEGMENT INFORMATION 2025 2024 Net sales $ 118,365 $ 128,133 Cost of goods sold 100,359 111,411 Gross profit 18,006 16,722 Operating expenses: Selling 4,803 3,446 General and administrative 10,790 11,709 Research and development 1,172 1,191 Restructuring charges 266 571 Total operating expenses 17,031 16,917 Income (loss) from operations 975 ( 195 ) Other expense: Interest expense ( 964 ) ( 744 ) Income (loss) before income taxes 11 ( 939 ) Income tax expense 263 356 Net loss $ ( 252 ) $ ( 1,295 ) 49 The Company’s long-lived tangible assets, including the Company’s operating lease assets recognized on the consolidated balance sheets were geographically located as follows as of December 31: SCHEDULE OF LONG LIVED TANGIBLE ASSETS 2025 2024 United States $ 8,876 $ 10,429 Mexico 2,015 2,445 China 1,328 1,497 Total long-lived tangible assets $ 12,219 $ 14,371 Export net from our U.S. domestic operations represent approximately 3.3 % and 3.4 % of consolidated net sales for the years ended December 31, 2025 and 2024, respectively. Net sales by our major EMS industry markets are as follows for the years ended December 31: SCHEDULE OF NET SALES BY EMS INDUSTRY MARKETS 2025 2024 Medical Device $ 31,930 $ 34,636 Medical Imaging 39,999 37,492 Industrial 30,940 35,517 Aerospace and Defense 15,496 20,488 Total net sales $ 118,365 $ 128,133 NOTE 10. COMMITMENTS AND CONTINGENCIES Litigation We are subject to various legal proceedings and claims that arise in the ordinary course of business. In our opinion, the amount of any ultimate liability with respect to these actions will not materially affect our consolidated financial statements or results of operations. Change of Control Agreements Since 2002, we entered into Change of Control Agreements (the Agreement(s)) with certain key executives (the Executive(s)). The Agreements provide an inducement for each Executive to remain as an employee in the event of any proposed or anticipated change of control in the organization, including facilitating an orderly transition, and to provide economic security for the Executive after a change in control has occurred. In the event of an involuntary termination in connection with a change of control as defined in the agreements, each Executive would receive their base salary, annual bonus at time of termination, and continued participation in health, disability and life insurance plans for a period of three years for officers and two years for all other participants. 50 NOTE 11. RESTUCTURING CHARGES During the year ended December 31, 2024, we incurred restructuring charges of $ 571 related to the closure and consolidation of our Blue Earth, Minnesota production facility, which was substantially completed in the fourth quarter of 2024. During the year ended December 31, 2025, the Company incurred $ 266 of restructuring charges, in connection with activities related to the Blue Earth facility and additional staff reductions in the first quarter of 2025. The following table summarizes the related activity for the twelve months ended December 31, 2025 and 2024: SCHEDULE OF RESTRUCTURING CHARGES Facility Consolidation Workforce Reductions Total January 1, 2024 $ - $ - $ - Charges 571 - 571 Cash payments ( 417 ) - ( 417 ) December 31, 2024 $ 154 $ - $ 154 Charges 31 235 266 Cash payments ( 185 ) ( 235 ) ( 420 ) December 31, 2025 $ - $ - $ - NOTE 12. RELATED PARTY TRANSACTIONS David Kunin, our Chairman, is a minority owner of Abilitech Medical, Inc. We had accounts receivable related to Abilitech of $ 226 as of December 31, 2023. Payments of $ 33 were received during the year ended December 31, 2024 and we wrote off the remaining receivables during 2024. Abilitech has ceased operations and therefore we do not believe that Abilitech will pay the Company for outstanding accounts receivable. The Company believes that transactions with Abilitech were on terms comparable to those that the Company could reasonably expect in an arm’s length transaction with an unrelated third party. David Kunin, our Chairman, is a minority owner (less than 10 %) of Marpe Technologies, LTD an early-stage medical device company dedicated to the early detection of skin cancer through full body scanners. Mr. Kunin is also a member of the Board of Directors of Marpe Technologies. The Company worked with Marpe Technologies to apply for a grant from the Israel-United States Binational Industrial Research and Development Foundation, a legal entity created by Agreement between the Government of the State of Israel and the Government of the United States of America (“BIRD Foundation”). The parties were successful in receiving approval for a $ 1,000 conditional grant. The Company and Marpe Technologies will each receive $ 500 from the BIRD Foundation and, among other obligations under the grant, each is required to contribute $ 500 to match grant funds from the BIRD Foundation. The Company met its obligation by providing certain services at cost or with respect to administrative services at no cost to Marpe Technologies. The total value of the Company’s contribution will not exceed $ 500 . Marpe is engaged in raising funds for its operations, which funds are necessary to pay for the Company’s services beyond its contribution. The Company will receive a 10 -year exclusive right to manufacture the products of Marpe Technologies. There can be no assurances that Marpe Technologies’ medical device operations will be commercially successful, that Marpe Technologies will be successful in raising additional funds to finance its operations or, if commercially successful, the Company will recover the value of services provided to Marpe if not paid when the services are provided. The transactions between the Company and Marpe Technologies have been approved by the Audit Committee pursuant to the Company Related-Party Transactions Policy. During the twelve months ended December 31, 2025, we recognized no net sales to Marpe Technologies. During the twelve ended December 31, 2024, we recognized net sales to Marpe Technologies of $ 8 . As of December 31, 2025, we have no outstanding accounts receivable. The Company believes that transactions with Marpe are on terms comparable to those that the Company could reasonably expect in an arm’s length transaction with an unrelated third party. NOTE 13. SUBSEQUENT EVENTS Financing Arrangement Waiver and Amendment On February 27, 2026, the Company entered into a Waiver and Amendment. Under the Waiver and Amendment, Bank of America waived certain financial covenant defaults related to the Company’s Consolidated Leverage Ratio, Fixed Charge Coverage Ratio, and Consolidated EBITDA for the quarter ended December 31, 2025. The Waiver and Amendment also modified multiple provisions of the Credit Agreement, including revised definitions, updated borrowing base mechanics, revised financial covenants (including new EBITDA thresholds), adjustments to the revolving commitment levels, an increase in applicable borrowing rate, and updates limitations on foreign subsidiary investments and transfers. New Financing Arrangement On March 20, 2026, we entered into a new Credit and Security Agreement with Associated Bank, National Association, which provides for a revolving credit facility of up to $ 15,000 , subject to a borrowing base based on eligible accounts receivable and inventory, and a $ 2,200 term loan (the “Associated Facility”). The Associated Facility includes a sublimit of $ 1,500 for letters of credit and is secured by substantially all of our assets in the United States of America, and the facility and term loan each mature in March 2029 . Borrowings under the Associated Facility bear interest, at our option, at a defined base rate, or at one-month or three-month Term Secured Overnight Financing Rate, plus 2.00% in the case of revolving credit borrowings and plus 2.25% in the case of the term loan. The Associated Facility contains customary affirmative and negative covenants that restrict or limit our ability to incur additional indebtedness, create liens, make investments, sell assets, pay dividends or engage in certain transactions without lender consent. This agreement also requires us to comply with financial covenants, including maintaining a Fixed Charge Coverage Ratio of 1.10 to 1.00, which measures the ratio of EBITDA, as defined to exclude certain other non-cash items, and less unfunded capital expenditures, to fixed charges such as interest as well as debt and capital lease principal payments. The Associated Facility agreement includes broad and customary events of default such as non-payment of obligations, breaches of representations or covenants, unauthorized liens, insolvency events, material adverse changes, cross-defaults to other significant indebtedness, and change-of-control triggers. Additional events include unsatisfied judgments, loss of lender lien priority, defaults under material business agreements, impairment of key intellectual property, destruction of collateral, and certain ERISA, hedging, or legal compliance violations. Upon an event of default, including the lender’s determination that a material adverse event has occurred, as defined by the agreement, the lender may accelerate all obligations, terminate the commitments, and exercise its full rights and remedies against the collateral. 51 Equity Incentive Plan In March 2026, the Company’s Board of Directors approved the 2026 Equity Incentive Plan (the “2026 Plan”), subject to shareholder approval at the upcoming annual meeting in May 2026. The 2026 Plan would succeed the Company’s 2017 Stock Incentive Plan and authorize 250,000 shares for various equity- and cash-based awards. No awards have been granted under the Plan, and shareholder approval is pending. Tarriff Legislation In February 2026, the U.S. Supreme Court ruled that the International Emergency Economic Powers Act (“IEEPA”) does not authorize the President to impose tariffs, resulting in the termination of all IEEPA-based tariffs effective February 24, 2026. Following this ruling, the Administration imposed a temporary 10% global tariff on most imported products under Section 122 of the Trade Expansion Act of 1962, effective February 24, 2026, for a 150-day period. These new tariffs apply broadly to manufactured goods and component parts. Because the legislation was enacted after December 31, 2025, its effects are not reflected in our consolidated financial statements. The Company is evaluating the potential impact of these tariff actions on future material costs and sourcing decisions. Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure None.